Top News

Press Release | September 22, 2016

Scott Whitaker, president and CEO of the Advanced Medical Technology Association (AdvaMed), issued a statement after introduction of bipartisan legislation in the U.S. Senate designed to ensure Medicare beneficiary access to needed medical technologies and services.

Press Release | September 20, 2016

WASHINGTON, D.C. – Andrew Fish, executive director of AdvaMedDx, issued the following statement on today’s Senate HELP Committee hearing on laboratory testing in the era of precision medicine:

Press Release | September 12, 2016

Lima, Peru – Christopher L. White, senior executive vice president and general counsel of AdvaMed (the Advanced Medical Technology Association), issued the following statement following the Asia-Pacific Economic Cooperation (APEC) Business Ethics for Small- and Medium-Sized Companies Forum:


September 27, 2016 to September 28, 2016
| Washington, DC

During this workshop, you will be provided with the road-map and practical applications to successfully navigate the many potential reimbursement pitfalls. After an overview of current... Read More

September 28, 2016 to September 29, 2016
| Washington, DC

This next level reimbursement workshop was created with the more advanced professional in mind. You'll walk away from this workshop with more insight into the complex and critical nature of... Read More

Industry News

Little Falls, NJ - Cantel Medical Corp.
(NYSE:CMN) announced today the appointment of Jorgen B. Hansen as the Company’s President and Chief Executive Officer, effective today, consistent with the Company’s long-term CEO succession plan. Mr. Hansen also will become a member of the Board of Directors. Mr. Hansen succeeds Andrew A. Krakauer, who will serve as a Senior Advisor for the Company until October 15, 2016.
Cohera Medical Inc.
RALEIGH, N.C., July 12, 2016 (GLOBE NEWSWIRE) Cohera Medical, Inc., a leading innovator and developer of absorbable surgical adhesives and sealants, today announced that it has received Investigational Device Exemption (IDE) approval from the United States Food and Drug Administration (FDA) to begin a prospective, multicenter, randomized clinical trial for its Sylys® Surgical Sealant device.
Fox News Channel
Heart disease is the number one cause of death for both men and women in the United States. Claiming approximately 1 million lives per year, heart attacks alone strike someone every 43 seconds. On January 20, 2014, that someone was me.
Opioid addiction, abuse, and overdose are at the forefront of our national dialogue. But by casting opioids as the villain, this important conversation is missing an essential element: how best to treat the chronic pain that afflicts 100 million Americans, including many of our wounded warriors. Chronic pain is a multifaceted problem with a range of causes and solutions, not a two-dimensional condition that can only be treated with opioids.
ReVision Optics won pre-market approval from the FDA yesterday for its Raindrop near vision inlay, a corneal implant designed to treat presbyopia.The Raindrop is a microscopic hydrogel inlay placed in the cornea of the patient’s non-dominant eye during a 10-minute procedure to gently reshape the anterior curvature of the cornea to provide near and intermediate vision, Lake Forest, Calif.-based ReVision said.

Twitter Feed

September 23, 2016 - 12:47pm
RT : Partnering is here! Log on to MedTech Connect to start before . Register now for access!
September 23, 2016 - 12:35pm
More patients should consider , new guidelines say